FUJIFILM Diosynth Biotechnologies vs WuXi Biologics: CDMO Comparison

Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
12
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics
Shanghai, CN · Wuxi, CN
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Modalities
CAR-T, Cell Therapy, AAV, ADC

Key differences

  • FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (12 active certificates vs 3) — stronger EU footprint.
  • FUJIFILM Diosynth Biotechnologies has stronger MHRA / UK coverage (6 compliant certificates vs 1).

On a 13-modality CDMO landscape, both FUJIFILM Diosynth Biotechnologies and WuXi Biologics qualify as AAV manufacturers; WuXi Biologics carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both FUJIFILM Diosynth Biotechnologies and WuXi Biologics qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: FUJIFILM Diosynth Biotechnologies vs WuXi Biologics

How do FUJIFILM Diosynth Biotechnologies and WuXi Biologics compare on European GMP coverage?

FUJIFILM Diosynth Biotechnologies holds 12 active EMA GMP certificates and 6 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for AAV manufacturing — FUJIFILM Diosynth Biotechnologies or WuXi Biologics?

Both FUJIFILM Diosynth Biotechnologies and WuXi Biologics are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

FUJIFILM Diosynth Biotechnologies carries a Signal Score of 84/100 and WuXi Biologics carries 84/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating FUJIFILM Diosynth Biotechnologies and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.